Bone Therapeutics Aktie

Kaufen

Verkaufen

0,0020 EUR -0,0001 EUR -4,76 %

23.12.2025

FSE

0,0022 EUR -0,0001 EUR -4,35 %

23.12.2025

EBR

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Bei einem anderen Broker handeln

Marktkap.1,44 Mio. EUR

Div. Rendite0,00%

WKNA14NHV

ISINBE0974280126

SymbolBNZPF

Bone Therapeutics Aktien News

Sortieren:Datum Meistgelesen

28.10.24GlobeNewswireBioSenic provides third quarter 2024 Business Update

07.10.24GlobeNewswireBioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

30.09.24GlobeNewswireBioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the compositio

30.09.24GlobeNewswireBioSenic reports half year 2024 results

17.09.24GlobeNewswireVéronique Pomi-Schneiter stands down as BioSenic's Deputy CEO

19.08.24GlobeNewswireBioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.

14.08.24GlobeNewswireMedsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis

13.08.24GlobeNewswireMedsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform

13.08.24GlobeNewswireBioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

19.07.24GlobeNewswireBioSenic S.A. : Transparency notification received from Mr François Rieger

18.07.24GlobeNewswireBioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD

12.07.24GlobeNewswireBioSenic S.A. : Transparency notification received from Véronique Pomi

05.07.24GlobeNewswireMedsenic, subsidiary of BioSenic SA, extends key patent to the United States

02.07.24GlobeNewswireMedsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

28.06.24GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

21.06.24GlobeNewswireBioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds

14.06.24GlobeNewswireThe Enterprise Court of Nivelles approves the BioSenic restructuring plan

12.06.24GlobeNewswireBioSenic to host Annual General Meeting on July 12, 2024

06.06.24GlobeNewswireBioSenic announces 2023 full year results

31.05.24GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

27.05.24GlobeNewswireBioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles

24.05.24GlobeNewswireBioSenic provides First Quarter 2024 Business Update

30.04.24GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

26.04.24GlobeNewswireBioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles

24.04.24GlobeNewswireBioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023

18.04.24GlobeNewswireBioSenic S.A. : Transparency notifications received from François Rieger

12.04.24GlobeNewswireBioSenic provides further information on its restructuring plan

11.04.24GlobeNewswireBioSenic and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles

29.03.24GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

20.03.24GlobeNewswireBioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress

12.03.24GlobeNewswireBioSenic releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease

29.02.24GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

02.02.24GlobeNewswireBioSenic raises €500,000 in private placement of new shares with established new investors

31.01.24GlobeNewswireBioSenic provides support to forthcoming European conference on graft-versus-host disease

30.01.24GlobeNewswireBioSenic patent granted in Canada for broader protection of ATO therapeutic platform

25.01.24GlobeNewswireBioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress

23.01.24GlobeNewswireBioSenic files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis

15.01.24GlobeNewswireBioSenic S.A. : Transparency notifications received from François Rieger

15.01.24GlobeNewswireBioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment

10.01.24GlobeNewswireBioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer

Bone Therapeutics News

Bone Therapeutics News: auf dieser Seite finden Sie alle Bone Therapeutics News und Nachrichten zur Bone Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bone Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bone Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.